Profile data is unavailable for this security.
About the company
Appili Therapeutics Inc. is a Canada-based biopharmaceutical company focused on drug development for infectious diseases and medical countermeasures. The Company is advancing a diverse range of anti-infectives, including an FDA-approved ready-made suspension of metronidazole for the treatment of antimicrobial-resistant infections, a vaccine candidate to eliminate a serious biological weapon threat, and a topical antiparasitic for the treatment of a disfiguring disease. Its anti-infective product development portfolio includes three programs: LIKMEZ (ATI-1501), ATI-1701, and ATI-1801. ATI-1501 is its advanced commercial stage asset, a liquid oral taste-masked reformulation of the antibiotic metronidazole. ATI-1701 is a novel, live-attenuated vaccine for Francisella tularensis (F. tularensis). ATI-1801 is a novel topical formulation of paromomycin (15% w/w) under advanced clinical development for the treatment of cutaneous leishmaniasis, a disfiguring infection of the skin.
- Revenue in CAD (TTM)218.92k
- Net income in CAD-2.96m
- Incorporated2015
- Employees7.00
- LocationAppili Therapeutics Inc#21-1344 Summer StreetHALIFAX B3H 0A8CanadaCAN
- Phone+1 (902) 442-4655
- Fax+1 (902) 442-4655
- Websitehttps://appilitherapeutics.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Vaxil Bio Ltd | 0.00 | -76.00k | 557.76k | -- | -- | 0.575 | -- | -- | -0.0277 | -0.0256 | 0.00 | 0.2435 | 0.00 | -- | -- | -- | -10.17 | -48.47 | -10.82 | -73.00 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 29.92 | -- | -- | -- |
| Waverley Pharma Inc | 1.51m | -367.12k | 810.00k | -- | -- | -- | -- | 0.538 | -0.0068 | -0.0068 | 0.0279 | -0.0437 | 0.9855 | 4.24 | 58.65 | -- | -24.03 | -38.03 | -- | -122.91 | 39.48 | 18.66 | -24.38 | -101.43 | 0.0382 | -1.64 | 3.74 | -- | 15.36 | -16.30 | 57.42 | -- | -- | -- |
| Appili Therapeutics Inc | 218.92k | -2.96m | 1.99m | 7.00 | -- | -- | -- | 9.07 | -0.024 | -0.024 | 0.0018 | -0.1276 | 0.1658 | -- | 0.3197 | -- | -224.12 | -143.75 | -- | -1,382.22 | -- | -- | -1,352.14 | -2,076.82 | -- | -3.50 | -- | -- | -87.86 | -12.79 | 30.58 | -- | 16.92 | -- |
